TIDMOPTI

RNS Number : 2341V

OptiBiotix Health PLC

26 January 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Result of General Meetings of Warrant Holders

Further to the announcement made on 23 December 2016, OptiBiotix Health plc (AIM: OPTI), announces that at the General Meeting of Warrant Holders held on 24 January 2017, all resolutions were duly passed.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

 
 OptiBiotix Health plc                         www.optibiotix.com 
 Stephen O'Hara, Chief Executive                      Contact via 
                                                   Walbrook below 
 
 Cairn Financial Advisers LLP                       Tel: 020 7213 
                                                             0880 
 Liam Murray 
 
 finnCap (Broker)                                   Tel: 020 7220 
                                                             0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate 
  Finance) 
 Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                            Tel: 020 7933 8780 or 
                                        optibiotix@walbrookpr.com 
 Anna Dunphy                                       Mob: 07876 741 
                                                              001

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROMOKADKQBKDNDB

(END) Dow Jones Newswires

January 26, 2017 09:06 ET (14:06 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Optibiotix Health Charts.